Replies to post #216096 on Avid Bioservices Inc (CDMO)

[md1225]

My understanding of the future of oncology is there is no such thing as single agent. The cure for cancer lies in combo therapy. Is Opdivo avastin Yervoy truly single agents when They all need loading doses of prednisone dexamethasone and NS pretreatment and during to control the dangerous immune cascade? Pretreat all patients with bavituximab and use low dose of currently approved io meds with bavituximab bimonthly and now we are on the cusp of a cure.

[biopharm]

You just don't understand. Bavituximab is NOT a single agent IO drug, there is NO point to compare to other single agent IO drug.

Jq1234, The fact of the matter is no other agent combines safely and as effectively with as many chemos, irradiation, or Immuno-Oncology drugs as Bavituximab does and more importantly...

No other drug reduces MDSC's or chronic inflammation as Bavituximab does and as a matter of fact...

No other drug compares to what Bavituximab or in general, what a PS Targeting drug such as Bavituximab does. Since combination is the name of the game in this paradigm shift of IO drugs.... Peregrine Pharmaceuticals Bavituximab is sitting front and center at heart of the Immuno-Oncology, because it is so safe and effective in optimizing an immune response.

So when you bring up about Bavituximab not being a single agent IO drug and the fact that no one can compare Bavituximab to other single agents, it is exactly why there are more posters than any other board on IHUB that have about 2,000 posts+ each. Simmering nicely as May 1st stock options near and Avid manufacturing being aligned up, ready for mass manufacturing.

This is just another intangible that shows anyone following this paradigm shift closely is expecting some big pops to occur sooner or later and everyone making sure they are positioned and the shelf is full of PPHM shares. Hope all is well there and enjoy the show : )

Remember, no matter what ones argument is or how it is portrayed here.... no one shows up here unless it is for a very good reason. A hell of a lot of greedy financial reasons attracts all types and the story will be told soon enough.

[bidrite]

literally there are hundreds if not thousands of drugs claiming they enhance Yervoy/Keytruda/Opdivo in preclinical model! Bavituximab is just one of many with iffy preclinical combo data.

How many of those thousands are in a pivotal PHIII trial having received FTD? Answer: zero